The med-tech biopharmaceutical company SOM Biotech, specializing in repurposing drugs to treat rare nervous system diseases, has concluded a worldwide license agreement with Corino Therapeutics Inc. to clinically develop and market the drug SOM0226 against transthyretin amyloidosis (ATTR). Before this licensing agreement had been reached, the drug achieved very promising results in a Phase 2…

SOM Biotech was selected to present at the 2017 New York Venture Summit in front of more than 100 top tier VCs, Corporate VCs and Angel Investors. New York, July 18th-19th, 2017. Dr. Raúl Insa, SOM Biotech CEO, and Michael Greenberg, VP Business Development, were attending this relevant financing event. Further information at NY Venture Summit…

Dr. Raúl Insa, SOM Biotech CEO, was invited to the 21st Summer School of the University of Barcelona to make a Lecture on Drug Repurposing in rare diseases. The 1-week course was entitled "Rare Diseases, from patient to its cure".  Dr. Insa had the opportunity to explain the audience SOM Biotech's Business model and how the company 'merges' these two…

Dr. Raúl Insa, SOM Biotech CEO, was the invited speaker at Closing Session of 9th Summer School on Medicines (SSM9). This event took place in Barcelona from 2 to 7 July 2017. SSM9 is structured to cover the whole process that leads from ideas and projects to drugs reaching the market, including visits to research centers…

SOM Biotech closed €2M funding round on January 2017 where 18 international investors from 10 different countries participated such as Monaco, Poland, UK, USA, India and South Korea among others. Most of the super-business angels involved include former pharmaceutical executives, which shows trust in SOM’s business model and its future vision. Additionally, SOM Biotech opened…

SOM Biotech attended the World Orphan Drug Congress USA 2017 (WODC) hold in Washington, USA on April 19th-21st. More than 1,000 global attendees did not want to miss the opportunity to discuss the latest trends on Orphan Drugs, a $140Billion dollar market. Topics like pricing, reimbursement, M&A, commercialization, FDA’s considerations, scientific innovation, regional market analysis…